Clinical Validation

#Clinical validation concerns the concept of interest

BEST defines clinical validation as establishing that a test, tool or instrument acceptably identifies, measures or predicts the concept of interest. For biomarkers, its validation chapter distinguishes measurement of the target from the ability to measure or predict a relevant clinical concept.

Read which condition, outcome or clinical concept is being evaluated. A reliable measurement is not automatically a reliable indicator of disease, prognosis or treatment response. Those are different claims and may require different evidence.

Evidence: FDA-NIH BEST: validation and intended purpose / FDA-NIH BEST: analytical validation, clinical validation and utility

#Population and intended setting matter

BEST emphasizes specifying the purpose and setting of use. CDC's archived ACCE questions ask whether a genetic test has been evaluated in the populations to which it may be offered, along with clinical sensitivity, specificity, prevalence and predictive values.

Read who was studied and whether their circumstances resemble those of the intended users. Validation in one population should not be silently expanded to another. The ACCE source is a historical genetic-test framework, not a current universal regulatory checklist or a patient-specific interpretation guide.

Evidence: FDA-NIH BEST: validation and intended purpose / CDC archive: questions for genetic-test validity and utility

#Discovery findings are not the whole validation process

BEST states that exploratory and discovery studies are typically insufficient for biomarker validation. It describes devising and carrying out a process to collect and analyze analytical and clinical performance evidence appropriate to the intended purpose.

Read whether an interesting association has been followed by evidence suitable for the claimed use. A promising early finding can justify further investigation without establishing that a test is ready for care. This page does not prescribe a sample size, study design or numerical approval criterion.

Evidence: FDA-NIH BEST: validation and intended purpose

#A clinical signal is different from a benefit of use

BEST separates clinical validation from clinical utility, which concerns net improvement in outcomes or useful information about diagnosis, treatment, management or prevention. Its validation chapter also warns that fitness for one purpose need not be sufficient for another regulatory purpose.

Read both what a result means and what happens when it is used. A clinically informative test may still need evidence about downstream decisions, harms and benefit. Mynd makes no validation, approval or clinical-performance claim for a particular product on this page.

Evidence: FDA-NIH BEST: analytical validation, clinical validation and utility / FDA-NIH BEST: validation and intended purpose

Source note

The sections above were checked against the linked sources. No clinical review has been performed. This is general research education, not a clinical guideline.